Baudax Bio, Inc. (BXRX)
Baudax Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Malvern, PA, US. The stock last traded at $0.02, up 7.39% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -4633.2%. Its beta of 1.58 implies it has historically moved more than the broad market.
Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-NSAID pain medications. The company's research and development portfolio features several candidates: BX1000, an intermediate-acting neuromuscular blocker currently in Phase II trials; BX2000, an ultra-short-acting variant of the same class, undergoing Phase I investigation; BX3000, an agent intended to reverse neuromuscular blockade; and Dex-IN, a unique intranasal delivery system for dexmedetomidine. Founded in 2019, the firm operates from its base in Malvern, Pennsylvania.
Baudax Bio, Inc. is most often compared with the following Healthcare names: